CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE Insider Trading

CEO Conrad Wai sells 220,426 shares of CLOV at $3.99; 10b5-1 plan execution; stock up 58.3% in 30 days.

Conrad Wai, CEO of Counterpart Health, sold 220,426 shares of Clover Health at $3.99 on 2026-05-28 under a pre-arranged 10b5-1 trading plan adopted on 2025-03-03, reducing his holdings from 1.61M shares to 1.39M shares. The sale occurs against a backdrop of sharp recent price appreciation: the stock has risen 58.3% over the prior 30 days and 100.0% over the prior 90 days, trading at $4.18 currently versus a 52-week high of $3.92. At the same ticker, Wai's prior two sales (2025-07-23 and 2025-07-22) were followed by negative 30-day and 90-day returns, though this transaction is scheduled under the 10b5-1 plan rather than discretionary. The company reported $749.2M in latest quarterly revenue (+40.3% annual growth) and $27.3M in net income, though it posted negative full-year net income over its most recent fiscal year, presenting a mixed financial picture.

Director Anna U Loengard buys 26,500 shares at $2.59–$2.60 for $68,755; holding surges to 29,610 shares (+852.1%)

Director Loengard executed 2 separate open-market purchases totaling 26,500 shares for $68,755.00 on 2025-08-13, elevating her stake from 3,110 to 29,610 shares—a gain of +852.1% in absolute holdings. Her prior 5 trades at CLOV were all buys, and all showed positive 90-day returns (ranging +43.8% to +186.0%), indicating she has demonstrated consistent timing at this ticker. Against this pattern, the current macro backdrop is notably challenging: the stock trades at -46.7% from its 52-week high, down -27.6% over 90 days, and the company reported negative net income of $-10.6M alongside -32.6% annual revenue decline. The timing signal must be weighed against the company's deteriorating fundamentals—her historical success at CLOV does not guarantee predictive power in a materially changed business environment.

Director Garipalli Vivek purchased 446,980 shares for $998,996.60 across two transactions at $2.24 and $2.17, raising holdings to 1.86M shares (+31.7%).

Garipalli Vivek, a director at Clover Health, executed 2 separate purchases totaling 446,980 shares for $998,996.60 at a blended average price of $2.23 on August 7–8, 2025, increasing his holdings by 31.7% to 1,856,247 shares. His timing pattern at CLOV is noteworthy: his prior 2 buys at this ticker (June 2024 and August 2024) both delivered strong 90-day returns (+162.3% and +95.2%), suggesting a track record of favorable entry points. His cross-ticker track record shows 2 prior buys with a 100% 90-day win rate and an average 90-day return of +128.7%. However, the company backdrop is challenging: annual revenue declined 32.6% year-over-year, the firm posted a net loss of $10,578,000.00 over its most recent full fiscal year, and the stock has fallen 54.8% from its 52-week high and is down 31.2% over the past 30 days. The scale of this purchase—nearly $1M deployed and a 31.7% increase in personal holdings—against deteriorating fundamentals and recent sharp price declines presents a material insider accumulation that investors should monitor closely for signals about the director's conviction or potential upcoming catalysts.

Wai Conrad (then-CEO, Counterpart Health) sold 209,797 shares of CLOV for $692,968.04 via 10b5-1 plan

Wai Conrad, who was CEO of Counterpart Health at the filing date, executed 2 separate sales totaling 209,797 shares for $692,968.04 on 2025-07-22 and 2025-07-23 at a blended average price of $3.30 per share. The sales reduced his holdings from 1,613,498 shares to 1,403,701 shares, a reduction of 209,797 shares. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-03, meaning the sales were scheduled and not discretionary decisions made at the time of the filing. With post-transaction holdings of 1,403,701 shares remaining, the insider retained a substantial equity position in the company.

Director Garipalli Vivek buys 531.7K shares of CLOV at $1.88; holdings rise 60.6% to 1.41M shares

Director Garipalli Vivek purchased 531,700 shares of Clover Health at $1.88 on 2024-08-09, increasing his holdings by 60.6% from 877,567 shares to 1,409,267 shares. The stock has appreciated 32.4% in the 30 days following the transaction and currently trades at $2.00, near its 52-week high. However, the company's fundamentals present a mixed picture: while it generated $356,260,000 in revenue last quarter with $7,408,000 in net income, annual revenue declined 41.5% year-over-year and the firm was unprofitable on a full-year basis. Across his open-market history, this director's prior buy showed a +50.9% 30-day return, but his historical timing pattern at the 90-day mark provides limited predictive power, and this transaction's longer-term outcome remains to be determined.

Director Garipalli Vivek buys 877.6K CLOV shares at $1.14 for $1.0M; stock now at $1.03, down -34.0% from 52-week high.

Director Garipalli Vivek initiated a new position in Clover Health with a $1.0M purchase of 877,567 shares at $1.14 on 2024-06-17, establishing 877.6K shares post-transaction with zero prior holdings. The purchase occurs in a company facing material headwinds: annual revenue declined -41.5% year-over-year, the company posted a net loss of $-19.2M in its latest quarter, and full-year net income was negative. The stock currently trades at $1.03, representing a -34.0% decline from the 52-week high of $1.56, suggesting the director's entry price of $1.14 was substantially above current valuation. This first-time director purchase into a structurally unprofitable, declining-revenue business warrants examination of whether market conditions or company fundamentals have deteriorated since the transaction date.